1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6030E0A2A6ED3813700258A1A004457A3
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-oncology-msl-team-excellence-benchmarking-key-performance-indicators?opendocument
18
19opendocument
2034.228.52.21
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Field Medical Excellence

Oncology MSL Team Excellence: Benchmarking Key Performance Indicators

ID: 5776


Features:

10 Info Graphics

10 Data Graphics

90+ Metrics

10 Narratives


Pages/Slides: 25


Published: 2023


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Oncology MSL Team Excellence: Benchmarking Key Performance Indicators”

STUDY OVERVIEW

In the ever-evolving Oncology landscape, where the roles of medical science liaisons (MSLs) are shaped by both traditional and virtual dynamics, staying at the forefront of KOL engagement is a strategic imperative. To excel in this dynamic environment, it's imperative to establish and monitor key performance indicators (KPIs) that gauge field performance and impact.

Best Practices, LLC undertook benchmarking research to uncover current and emerging trends in the management of Oncology field medical teams, particularly in the context of virtual and hybrid MSLs. This study empowers Oncology field medical leaders to ensure access to key external experts and effectively measure and enhance their teams' performance and impact.


KEY TOPICS

  • Field Challenges
  • KOL Access - Post Pandemic
  • Customer Engagement Preference
  • Proactive Outreach
  • F2F Meetings: Value and Ideal Mix

KEY METRICS

  • How would you rate the post-pandemic ability of Oncology MSLs to interact with KOLs and HCPs?
  • What do KOLs and HCPs served by Oncology MSL teams prefer in terms of engagement and support?
  • Approximately how many KOLs are currently supported by an individual MSL of each type at Oncology organizations?
  • Approximately how many F2F and virtual meetings are asked of each MSL within the Oncology organization?
  • Percentage of proactive interactions in Oncology segment
  • MSL proactivity index in Oncology segment
  • Are F2F interactions assigned a higher value on the Oncology MSL scorecard?
  • How many F2F meetings are targeted monthly?

SAMPLE KEY FINDINGS

  • Proactive outreach and product-specific discussion: On average, hybrid MSLs initiate 56% of KOL interactions, proactively discussing products in 62% of these interactions.

METHODOLOGY

Best Practices, LLC engaged Field Medical and other Medical Affairs leaders from 20 top Oncology manufacturers in this research through a benchmark survey. Deep-dive interviews were also conducted with field medical leaders to capture additional insights.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Biopharmaceutical; Health Care; Chemical


Companies Profiled:
AstraZeneca; Astellas; Bayer; Clovis Oncology; Eisai; Eli Lilly and Company; EMD Serono; GE Healthcare; Genentech; Ipsen; Kyowa Kirin; MacroGenics; Merck; Merus; Novartis; Pfizer; Rain Oncology; Roche; Servier; Takeda Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.